title: Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virus.
abstract: Although Δ⁹-THC has been approved to treat anorexia and weight loss associated with AIDS, it may also reduce well-being by disrupting complex behavioral processes or enhancing HIV replication. To investigate these possibilities, four groups of male rhesus macaques were trained to respond under an operant acquisition and performance procedure, and administered vehicle or Δ⁹-THC before and after inoculation with simian immunodeficiency virus (SIV(mac251), 100 TCID₅₀/ml, i.v.). Prior to chronic Δ⁹-THC and SIV inoculation, 0.032-0.32 mg/kg of Δ⁹-THC produced dose-dependent rate-decreasing effects and small, sporadic error-increasing effects in the acquisition and performance components in each subject. Following 28 days of chronic Δ⁹-THC (0.32 mg/kg, i.m.) or vehicle twice daily, delta-9-THC-treated subjects developed tolerance to the rate-decreasing effects, and this tolerance was maintained during the initial 7-12 months irrespective of SIV infection (i.e., +THC/-SIV, +THC/+SIV). Full necropsy was performed on all SIV subjects an average of 329 days post-SIV inoculation, with postmortem histopathology suggestive of a reduced frequency of CNS pathology as well as opportunistic infections in delta-9-THC-treated subjects. Chronic Δ⁹-THC also significantly reduced CB-1 and CB-2 receptor levels in the hippocampus, attenuated the expression of a proinflammatory cytokine (MCP-1), and did not increase viral load in plasma, cerebrospinal fluid, or brain tissue compared to vehicle-treated subjects with SIV. Together, these data indicate that chronic Δ⁹-THC produces tolerance to its behaviorally disruptive effects on complex tasks while not adversely affecting viral load or other markers of disease progression during the early stages of infection.
authors.affiliation: Department of Pharmacology, LSU Health Sciences Center, 1901 Perdido Street, New Orleans, LA 70112, USA. pwinsa@lsuhsc.edu
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Winsauer
authors.forename: Patricia E
authors.initials: PE
authors.lastname: Molina
authors.forename: Angela M
authors.initials: AM
authors.lastname: Amedee
authors.forename: Catalin M
authors.initials: CM
authors.lastname: Filipeanu
authors.forename: Robin R
authors.initials: RR
authors.lastname: McGoey
authors.forename: Dana A
authors.initials: DA
authors.lastname: Troxclair
authors.forename: Edith M
authors.initials: EM
authors.lastname: Walker
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Birke
authors.forename: Curtis Vande
authors.initials: CV
authors.lastname: Stouwe
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Howard
authors.forename: Stuart T
authors.initials: ST
authors.lastname: Leonard
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Moerschbaecher
authors.forename: Peter B
authors.initials: PB
authors.lastname: Lewis
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D015153:Blotting, Western; D013759:Dronabinol / Q000494:pharmacology*; D004361:Drug Tolerance; D008253:Macaca mulatta; D016133:Polymerase Chain Reaction; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism; D016097:Simian Acquired Immunodeficiency Syndrome / Q000503:physiopathology*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000302:isolation & purification
chemical_list: D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D013759:Dronabinol